Articles tagged "Mycophenolate mofetil"

2016 American Transplant Congress
Clinical Significance of Mycophenolic Acid Therapeutic Drug Monitoring in Kidney Transplant Recipients.
C.-D. Kim, J.-H. Cho, K. Kim, M. Kim, W. Do, Y. Yang, T. Yim, I. Hwang, J.-H. Lee, H.-Y. Jung, J.-Y. Choi, S.-H. Park, Y.-L. Kim.
Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Background: Mycophenolic acid (MPA) is a widely used immunosuppressant to prevent acute rejection in kidney transplant recipients (KTRs). However, clinical significance of MPA therapeutic drug…
2016 American Transplant Congress
Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.
K. Patel,¹ B. Stephany,² J. Barnes,¹ S. Bauer,¹ M. Spinner.¹
¹Department of Pharmacy, Cleveland Clinic, Cleveland, OH; ²Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH.
Pharmacokinetic (PK) data show reduced mycophenolic acid levels in transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. MMF dosing is not…
2016 American Transplant Congress
Mycophenolate Mofetil Dose Reduction Are Associated with the Risk of Acute Rejection and Graft Failure After Renal Transplantation.
A. El-Agroudy,¹ A. Taher,² A. Alaradi,² B. Alhayki,² S. Gareeb,² E. Farid.²
¹Internal Medicine, College of Medicine, Arabian Gulf University, Manama, Bahrain; ²Nephrology, Salmaniya Medical Complex, Manama, Bahrain.
Background: Mycophenolate mofetil (MMF) is a highly effective immunosuppressive agent in transplant therapy. Although MMF is generally well tolerated, optimal therapy may be limited by…
2016 American Transplant Congress
Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up.
Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ T. Nagai,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; ²Kidney Transplant Surgery, Aichi Medical University, Nagoya, Aichi, Japan.
Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression in order to further reduction of EVR and CNI was evaluated in clinical…
2015 American Transplant Congress
Short- and Long-Term Outcomes of Mycophenolate Versus Azathioprine in a Large Cohort of Renal Transplant Recipients
L. Bowman,¹ T. Horwedel,¹ J. Hagopian,¹ D. Brennan.²
¹Barnes-Jewish Hospital, St. Louis; ²Washington University School of Medicine, St. Louis.
Purpose: Early studies comparing mycophenolate mofetil (MMF) to azathioprine (AZA) post-renal transplantation demonstrated superiority of MMF over AZA for the prevention of acute rejection (AR).…
2015 American Transplant Congress
A Retrospective Review of a Renal Sparing Protocol in Orthotopic Liver Transplantation
B. Pierce,² J. Levitsky,^1,3 M. McLaughlin,² C. Richardson.²
¹Department of Medicine, Northwestern Medicine, Chicago, IL; ²Pharmacy, Northwestern Medicine, Chicago, IL; ³Hepatology, Northwestern Medicine, Chicago, IL.
Liver transplant recipients with pre-existing renal insufficiency are placed on a renal sparing protocol (RSP) consisting of delayed initiation of low-dose tacrolimus in addition to…
2015 American Transplant Congress
Pharmacogenomic Predictors of Acute Rejection in Kidney Transplant Recipients Identified Using a DNA Biobank Linked to Electronic Medical Records
K. Birdwell,¹ D. Velez-Edwards,² G. Vranic,⁵ J. Denny,^1,3 L. Choi,⁴ T. Ikizler,¹ D. Haas.¹
¹Medicine, Vanderbilt University Medical Center, Nashville, TN; ²Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, TN; ³Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN; ⁴Biostatistics, Vanderbilt University Medical Center, Nashville, TN; ⁵Medicine, University of Virginia, Charlottesville, VA.
Purpose: Risk for acute rejection (AR) complicating transplant immunosuppression may be affected by frequent variants in pharmacogenes. Using a DNA biobank linked to electronic medical…
2015 American Transplant Congress
Efficacy of Rituximab Sparing Protocol for ABO Incompatible Renal Transplant in Patients With Low Titers
S. Narumi,¹ Y. Watarai,¹ N. Goto,¹ T. Hiramitsu,¹ T. Yamamoto,¹ M. Tsujita,¹ M. Okada,¹ K. Futamura,¹ A. Takeda,² T. Kobayashi.³
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; ²Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; ³Applied Immunology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
[Introduction]Acute antibody mediated rejection (AMR) has been a major problem in ABO-incompatible kidney transplantation (ABOi-KTx), and currently mycophenolate mofetil and rituximab have been used to…
2015 American Transplant Congress
Efficacy and Safety of Desensitization Protocol Based On Rituximab Plus MMF in ABO-Incompatible Kidney Transplantation Without Splenectomy
K. Takahashi,¹ K. Saito,² S. Takahara,³ S. Fuchinoue,⁴ T. Yagisawa,⁵ A. Aikawa,⁶ Y. Watarai,⁷ N. Yoshimura,⁸ K. Tanabe,⁴ K. Morozumi,⁹ M. Shimazu.¹⁰
¹Niigata Organ Transplant Foundation, Niigata, Japan; ²Graduate School of Medical ＆ Dental Sciences, Niigata University, Niigata, Japan; ³Osaka University Graduate School of Medicine, Osaka, Japan; ⁴Tokyo Women's Medical University, Tokyo, Japan; ⁵Jichi Medical University Hospital, Tochigi, Japan; ⁶Toho University, Faculty of Medicine, Tokyo, Japan; ⁷Nagoya Daini Red Cross Hospital, Aichi, Japan; ⁸Kyoto Prefectural University of Medicine, Kyoto, Japan; ⁹Masuko Memorial Hospital, Aichi, Japan; ¹⁰Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
Purpose: An open-label, single arm, multicenter clinical study has been conducted in Japan for prospective examination of the efficacy and safety of desensitization protocol with…
2015 American Transplant Congress
"What's the Mileage?" Determining the Length of Time in Which Renal Function Returns to Pre-Calcineurin Discontinuation Levels in Patients With Interstitial Fibrosis
A. Diez, J. Von Visger, U. Nori, T. Pesavento, M. Henry, E. Davies, R. Pelletier.
The Ohio State University, Columbus.
Calcineurin Inhibitors (CNI) use may be associated with progressive renal dysfunction. Clinical trials have shown that CNI minimization or discontinuation may aid in improvement in…